Philadelphia chromosome-negative acute lymphoblastic leukemia: Therapies under development

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Although the prognosis of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) has steadily improved over the past decade, less than 50% of patients maintain their remission at 5 years. Several approaches have been explored in the past few years including: monoclonal antibodies-either 'naked' (rituximab) or in combination with an immunotoxin (calicheamicin or maytansin), plant toxin (ricin), or bacterial toxin (Pseudomonas or diphtheria), and a novel bispecific T-cell-engaging antibody (blinatumomab); chimeric antigen therapy using autologous T cells that target CD19-expressing ALL; and novel agents such as proteasome inhibitors, liposomal vincristine, hypomethylating agents, nelarabine and NOTCH1 inhibitors. This review summarizes treatment approaches currently under investigation for the treatment of adult Philadelphia chromosome-negative ALL.

Original languageEnglish (US)
Pages (from-to)2201-2212
Number of pages12
JournalFuture Oncology
Issue number14
StatePublished - Nov 1 2014


  • NOTCH1 inhibitors
  • chimeric antigen receptor therapy
  • immunotoxin
  • novel monoclonal antibodies
  • proteasome inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Philadelphia chromosome-negative acute lymphoblastic leukemia: Therapies under development'. Together they form a unique fingerprint.

Cite this